Neostem Inc (NYSEMKT:NBS)

AJHodge (< 20) Submitted: 7/15/2012 2:15:59 PM : Start Price: $0.66 NBS Score: -14.30

The sale of their Chinese assets has strengthened balance sheet and will allow company to focus its resources on developing its adult stem cell therapies. Amorcyte looks to be best candidate and a similar Baxter trial validates the potential.
The company also just received a grant for nearly $600k to further develop its VSEL applications.
Future looks good for NBS.